UK markets close in 6 hours 28 minutes

Moleculin Biotech, Inc. (0K2H.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
4.5680+0.0987 (+2.21%)
As of 05:51PM BST. Market open.
Full screen
Previous close4.4693
Open4.5680
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range4.5680 - 4.5680
52-week range0.3566 - 4.5680
Volume1,050
Avg. volume1,824
Market capN/A
Beta (5Y monthly)1.84
PE ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings date09 Aug 2024 - 13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the completion of its End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAr

  • PR Newswire

    Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported additional efficacy findings from the Company's ongoing Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with acute

  • PR Newswire

    Moleculin to Present at the Virtual Investor Pitch Conference

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 3:00 PM ET.